Boundless Bio Inc
Research Boundless Bio Inc (BOLD) on Bullrun: market cap USD 56.86M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBOLD
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 56.86M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 23.69M
- Free cash flow-USD 21.01M
Valuation Snapshot
latest market cap is USD 56.86M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 58.20M | -USD 47.21M | n/a | -2.6 | USD 17.87M | USD 49.04M | USD 98.65M |
| FY2024 | USD 0 | -USD 65.36M | -USD 63.38M | n/a | -3.85 | USD 26.59M | USD 47.63M | USD 150.64M |
| FY2023 | USD 0 | -USD 49.43M | -USD 47.49M | n/a | -40.65 | USD 23.71M | USD 2.20M | -USD 127.08M |
| FY2022 | USD 0 | -USD 45.90M | -USD 40.66M | n/a | -3.28 | USD 10.95M | USD 5.18M | -USD 81.70M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 56.86M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 26.89M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 64.67M | n/a | n/a | n/a |
About Boundless Bio Inc
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Boundless Bio Inc's market cap?
Boundless Bio Inc's market capitalization is USD 56.86M.
What does Boundless Bio Inc do?
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc.